Anti-lung cancer combined drug and use thereof

Through the combination of carboxylamide triazole and targeted drugs targeting gene mutations, the problem of drug resistance in targeted drugs is solved, which significantly inhibits the growth of lung cancer cells and improves the treatment effect, and is not obvious in animals. Toxic side effects.

WO2024235217A1PCT designated stage expired Publication Date: 2024-11-21GUANGDONG YINZHU PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093033
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-14
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing targeted drugs are prone to drug resistance problems when treating lung cancer, and it is difficult to effectively inhibit the growth of lung cancer cells related to gene mutations.

Method used

Carboxyamine triazole (CAI) is used in combination with targeted drugs targeting EGFR, ALK, MET, ROS1, BRAFV600 or RET gene mutations to jointly inhibit the growth and proliferation of lung cancer cells, reduce drug resistance, and improve drug sensitivity.

Benefits of technology

The combination of carboxylamide triazole and targeted drugs significantly inhibits the growth of lung cancer cells, improves the rate of tumor growth inhibition, reduces tumor volume, and has no obvious toxic side effects in animals, enhancing the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093033_21112024_PF_FP_ABST
    Figure CN2024093033_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is an anti-lung cancer combined drug, which comprises carboxyamidotriazole and an anti-tumor targeting drug for gene mutation and is mainly applied to the preparation of anti-lung cancer drugs. Specifically, a combined administration group of carboxyamidotriazole and osimertinib can significantly inhibit the growth and proliferation of a human lung cancer NCI-H1975 xenograft tumor in a nude mouse, and a combined administration group of carboxyamidotriazole and alectinib can significantly inhibit the growth and proliferation of NCI-H2228 cells. The combined administration of the carboxyamidotriazole and the anti-tumor targeting drug for gene mutation has a combined synergistic effect and does not have obvious toxic and side effects.
Need to check novelty before this filing date? Find Prior Art

Description

A combined anti-lung cancer drug and its application Technical Field

[0001] The present invention belongs to the field of medical treatment and medicine, and particularly relates to a combined anti-lung cancer drug and application thereof. Background Art

[0002] Carboxyamidotriazole (CAI) is a non-cytotoxic antitumor drug. Its chemical name is 5-amino-1-[3,5-dichloro-4-(4-chlorobenzoyl chloride)benzyl]-1H-1,2,3-triazole-4-benzamide, and its chemical structure is:

[0003] Current research indicates that CAI has a promising effect against a variety of tumors. It can inhibit the proliferation of endothelial cells and various tumor cell lines, including MDA-MB-231, OVCAR-3, and MCF-7. It can also inhibit the invasion of prostate cancer, bladder cancer, breast cancer, liver cancer, and glioblastoma. Clinical trials have shown that CAI has a mild anti-tumor effect and can be used in combined anti-tumor studies.

[0004] Preliminary research on the anti-tumor mechanism of CAI and its combination therapy has revealed the synergistic effect of CAI combined with sorafenib. The results showed that the combination of CAI and sorafenib can synergistically inhibit the growth of non-small cell lung cancer. This effect was confirmed in both in vivo and in vitro experiments. The mechanism of this synergistic effect may be the induction of cell apoptosis and the inhibition of NANOG expression. This combination can significantly reduce the dosage of sorafenib in vivo, but it does not reduce the efficacy. At the same time, it also effectively protects the weight of mice. Combined with the above reports, it shows that there is great room for research and development in the combination of carboxyamide triazoles.

[0005] Chinese invention patent application 200810212286.4 discloses an anti-tumor drug preparation containing carboxyamidotriazole and dexamethasone as active ingredients. In vivo animal experimental results showed that the inhibition rate of carboxyamidotriazole alone against mouse melanoma was 39.8%, while the inhibition rate when dexamethasone was injected intraperitoneally was 19.3%. The combined use of the two achieved an inhibition rate of 69.0% against melanoma transplants, both of which were significantly different from the control group.

[0006] Chinese invention patent application CN109674788A discloses the use of a combination of carboxyamidotriazole and an IDO1 inhibitor for anti-tumor treatment. Specifically, the present invention relates to the use of a combination of carboxyamidotriazole and one or more IDO1 inhibitors in the preparation of an anti-tumor drug for use in mammals. While research results on anti-tumor drugs continue to emerge, the search for more effective drugs and methods continues. Finding truly effective tumor elimination methods to achieve the goal of completely treating cancer cells in clinical tumor patients is a goal that industry insiders are diligently pursuing and that society as a whole desires.

[0007] Targeted drugs are drugs that specifically target tumor cells, killing cancer cells without affecting normal cells, thus improving treatment efficacy. Take osimertinib as an example. The principle behind this drug's effectiveness is that lung cancer (currently limited to lung cancer and not applicable to all tumor types) harbors a variety of genetic mutations, 50% of which harbor EGFR mutations. Research has found that this type of carcinogenesis (the process of cells evolving from normal cells to tumor cells) is driven by EGFR gene mutations. Osimertinib is a drug developed specifically for the EGFR protein. Therefore, genetic testing is used to determine which targeted drug to use, identifying the target for the cancer cells and providing the right treatment. For example, in lung cancer, patients harbor mutations in certain genes, most commonly epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and transmembrane receptor tyrosine kinase (ROS1). Targeted drugs are designed specifically for each gene mutation. However, existing targeted drug delivery methods present the problem of drug resistance.

[0008] Therefore, based on the above content, we explore the combined use of carboxyamide triazole and anti-tumor targeted drugs targeting gene mutations to reduce drug resistance and increase drug sensitivity, which has achieved the technical effect of enhancing synergy and can benefit more patients.

[0009] Summary of the Invention

[0010] In order to solve the above problems, the present invention provides a combined anti-lung cancer drug, which combines carboxyamide triazole with an anti-tumor targeted drug targeting gene mutations to achieve a synergistic technical effect without obvious toxic side effects.

[0011] In order to achieve the above object, the present invention adopts the following technical solutions:

[0012] A combined drug for treating lung cancer, comprising carboxyamidotriazole and an anti-tumor targeted drug targeting gene mutations.

[0013] Preferably, the anti-tumor targeted drug is selected from one or more of a targeted drug for EGFR gene mutation-positive, a targeted drug for ALK gene rearrangement-positive, a targeted drug for MET gene mutation-positive, a targeted drug for ROS1 gene rearrangement-positive, a targeted drug for BRAFV600 gene mutation and a targeted drug for RET fusion.

[0014] Further preferably, the targeted drug for EGFR gene mutation-positive is selected from at least one of osimertinib, icotinib, gefitinib, afatinib, ametinib, and dacomitinib.

[0015] Further preferably, the targeted drug for ALK rearrangement-positive is selected from at least one of crizotinib, alectinib, ceritinib, ensartinib, and brigatinib.

[0016] Further preferably, the targeted drug for MET gene mutation is savotinib; the targeted drug for ROS1 gene rearrangement positive is selected from at least one of crizotinib and entrectinib; the targeted drug for BRAFV600 gene mutation is selected from at least one of dabrafenib and trametinib; the targeted drug for RET fusion is pratinib.

[0017] Still more preferably, the combination drug comprises carboxyamidotriazole and osimertinib.

[0018] Still more preferably, the combined drug includes carboxyamidotriazole and alectinib.

[0019] Preferably, for the recipient, the dosage of carboxyamide triazole is 1-10 mg / kg; the dosage of the anti-tumor targeted drug is 0.05-10 mg / kg.

[0020] Preferably, the dosage of carboxyamide triazole is 1-4 mg / kg; the dosage of anti-tumor targeted drug is 0.05-0.1 mg / kg.

[0021] Preferably, the effective daily dosage of carboxyamide triazole is 50-300 mg; the dosage of the anti-tumor targeted drug is 2 mg-1200 mg / day.

[0022] More preferably, the effective daily dosage of carboxyamide triazole is 150-300 mg; and the dosage of the anti-tumor targeted drug is 150 mg-600 mg / day.

[0023] Preferably, the effective daily dosage of carboxyamide triazole is 25-195 mg, preferably 50-150 mg / day; the human dosage calculated from animal experiments is about 1-4 mg / kg, preferably 1.626-3.252 mg / kg; the human dosage of osimertinib calculated from animal experiments is about 0.05-0.1 mg / kg, preferably 0.0813 mg / kg.

[0024] Preferably, the effective daily dosage of alectinib is 600-1560 mg / day; in some embodiments within the scope of the present invention, it may be 1200 mg / day or 840 mg / day; the effective daily dosage of crizotinib is 125-325 mg / day; in some embodiments within the scope of the present invention, it may be 250 mg / day; the effective daily dosage of ceritinib is 225-585 mg / day, and in some embodiments within the scope of the present invention, it may be 450 mg / day; the effective daily dosage of ensartinib is 112-300 mg / day; in some embodiments within the scope of the present invention, it may be 225 mg / day; the effective daily dosage of brigatinib is 45-240 mg / day, and in some embodiments within the scope of the present invention, it may be 45-180 mg / day, and in some embodiments within the scope of the present invention, it may be 90-180 mg / day.

[0025] Preferably, the effective daily dosage of osimertinib is 40-104 mg / day, preferably 56 mg / day; the effective daily dosage of icotinib is 187.5-487.5 mg / kg, preferably 245.5 mg / day; the effective daily dosage of gefitinib is 125-325 mg / day, which may be 250 mg / day in some embodiments within the scope of the present invention; the effective daily dosage of afatinib is 20-52 mg / day, preferably 28 mg / day; the effective daily dosage of ametinib is 55-143 mg / day, preferably 77 mg / day; the effective daily dosage of dacomitinib is 22.5-58.5 mg / day, preferably 31.5 mg / day.

[0026] The effective daily dosage of savotinib is 200-780 mg / day, preferably 180-420 mg / day; the effective daily dosage of entrectinib is 300-780 mg / day, preferably 420 mg / day.

[0027] The effective daily dosage of dabrafenib is 150-390 mg / day, preferably 210 mg / day; the effective daily dosage of trametinib is 1-2.6 mg / day, preferably 1.4 mg / day.

[0028] The effective daily dosage of pralatinib is 200-520 mg / day, preferably 280 mg / day.

[0029] Preferably, the combined drug comprises, by weight, 20-40 parts of carboxyamide triazole and 0.5-1.5 parts of osimertinib.

[0030] Preferably, the carboxyamide triazole preparation is a soft capsule and osimertinib is a tablet.

[0031] Preferably, the carboxyamide triazole and the anti-tumor targeted drug targeting gene mutation can be administered simultaneously, separately or sequentially.

[0032] The present invention also relates to the use of a combined drug in the preparation of anti-lung cancer drugs.

[0033] Preferably, the effects of the combined drug include one or more of reducing tumor volume, increasing tumor growth inhibition rate, reducing relative tumor volume, reducing relative tumor growth rate and increasing tumor inhibition rate.

[0034] The present invention also relates to a composition comprising the above-mentioned combined drug, namely carboxyamide triazole and an anti-tumor targeted drug targeting gene mutation, and the composition is used in the preparation of an anti-lung cancer drug.

[0035] Preferably, the composition comprises a pharmaceutically acceptable carrier or excipient.

[0036] Preferably, the dosage form of the composition is selected from oral solution, capsule, oral suspension, solid dispersion, capsule, sustained-release agent, granule, tablet, injection, ointment, patch or implant.

[0037] Compared with the prior art, the present invention has the following beneficial effects:

[0038] (1) The combined administration of carboxyamidotriazole and osimertinib significantly inhibited the growth and proliferation of human lung cancer NCI-H1975 xenograft tumors in nude mice (P<0.01, P<0.01); the combination of the two drugs had a synergistic effect (P<0.05, P<0.05, combination index>1.15).

[0039] (2) Co-administration of carboxyamidotriazole and osimertinib did not inhibit animal weight gain. The average animal weight increased by 8.51%-11.04% (1.63g-2.17g) compared to the start of the experiment on Day 0. No drug-related animal deaths or other obvious drug-related toxicities were observed during the experiment.

[0040] (3) Carboxyamide triazole has a significant synergistic effect when combined with targeted drugs for EGFR gene mutation, targeted drugs for ALK rearrangement, targeted drugs for MET gene mutation, targeted drugs for ROS1 gene rearrangement, targeted drugs for BRAFV600 gene mutation and targeted drugs for RET fusion.

[0041] (4) The combined administration of carboxyamidotriazole and alectinib can significantly inhibit the growth and tumor proliferation of human lung adenocarcinoma NCI-H2228 cells, and the combination of the two has a significant synergistic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] FIG1 is a graph showing changes in animal body weight in Comparative Examples 1-3 and Examples 1-2;

[0043] FIG2 is a graph showing the weight change rates of animals in Comparative Examples 1-3 and Examples 1-2;

[0044] FIG3 is a graph showing changes in tumor volume in Comparative Example 1-3 and Example 1-2;

[0045] FIG4 is a graph showing changes in relative tumor volume in Comparative Examples 1-3 and Examples 1-2;

[0046] FIG5 is a bar graph showing changes in tumor weight in Comparative Examples 1-3 and Examples 1-2;

[0047] FIG6 is a comparison of tumors at different times between Comparative Example 1-3 and Example 1-2;

[0048] FIG7 is a graph showing changes in tumor volume in Comparative Example 4-6 and Example 4-5;

[0049] FIG8 is a graph showing changes in relative tumor volume in Comparative Example 4-6 and Example 4-5;

[0050] FIG9 is a bar graph showing changes in tumor weight in Comparative Examples 4-6 and Examples 4-5. DETAILED DESCRIPTION

[0051] The present invention will be further described in detail below with reference to specific examples. The following examples are not intended to limit the present invention but are merely intended to illustrate the present invention. The experimental methods used in the following examples are generally based on conventional conditions unless otherwise specified. The materials and reagents used in the following examples are all commercially available unless otherwise specified.

[0052] Carboxyamidotriazole (CAI), osimertinib (AZD9291), and alectinib hydrochloride were provided by Guangdong Yinzhu Pharmaceutical Technology Co., Ltd. The detailed information is shown in Table 1 .

[0053] Table 1 Drugs and related information

[0054] Example 1

[0055] An anti-tumor combination drug comprises, by weight: 40 parts of carboxyamide triazole (PO, QD×21) and 1 part of osimertinib (PO, QD×21).

[0056] Example 2

[0057] An anti-tumor combination drug comprises, by weight: 20 parts of carboxyamide triazole (PO, QD×21) and 1 part of osimertinib (PO, QD×21).

[0058] Comparative Example 1

[0059] Single component osimertinib 1 portion (PO, QD×21).

[0060] Comparative Example 2

[0061] Single component carboxyamine triazole 40 parts (PO, QD×21).

[0062] Comparative Example 3

[0063] Single component carboxyamine triazole 20 parts (PO, QD×21).

[0064] control group

[0065] The vehicle control group was free of carboxytriazole and osimertinib and received vehicle (PO, QD×21).

[0066] 1. Pharmacodynamics Experimental Evaluation of Examples 1-2 and Comparative Examples 1-3:

[0067] 1. Experimental Animals

[0068] 1.1 Animal Information

[0069] Nude female BALB / c mice, 8-10 weeks old, weighing 18-20 g, with a deviation of approximately ±20% of the mean body weight. 80 mice were vaccinated, with 60 mice enrolled in each group.

[0070] Animal source: Jiangsu Jicui Yaokang Biotechnology Co., Ltd., production license number: SCXK(Su)2018-0008, animal certificate number: 202301350.

[0071] 1.2 Animal husbandry

[0072] The mice were kept in SPF environment, IVC cages, 5 mice per cage, temperature: 20-26°C, humidity: 40-70%, light: 12-h day and night alternation, and feed: irradiated rat feed purchased from Beijing Keao Xieli Feed Co., Ltd., with free access to food.

[0073] Drinking water: city tap water, filtered and sterilized before drinking.

[0074] Bedding: corn cobs, purchased from Keao Xieli, sterilized after high pressure, and replaced once a week.

[0075] Adaptive feeding: Before the experiment, mice were given an adaptive feeding period of no less than 7 days.

[0076] Animal identification: Each mouse cage is hung with an experimental information card, which includes mouse information, cell inoculation information, animal experiment information, and experimenter information. Mice are marked with ear tags.

[0077] 1.3 Laboratory Animal Operation and Management Standards

[0078] During the experiment, all experimental animals were kept in the SPF-level animal laboratory of Shanghai Medicilon Biotechnology Co., Ltd., and the animal laboratory personnel of Shanghai Medicilon Biotechnology Co., Ltd. were responsible for daily care and experimental research.

[0079] All operations and management of experimental animals strictly complied with the Shanghai Medicilon Guidelines for the Use and Management of Laboratory Animals.

[0080] 2. Experimental Materials

[0081] 2.1 Solvent formulation and storage conditions of dosing solution

[0082] 2.1.1 CAI

[0083] Solvent: 100% PEG400

[0084] Storage conditions of the dosing solution: Store at room temperature away from light, with a shelf life of 3 days.

[0085] 2.1.2 AZD9291

[0086] Solvent: 0.5% MC

[0087] Storage conditions of the dosing solution: Store at 4°C away from light, with a shelf life of 7 days.

[0088] 2.2 Cell lines

[0089] Human lung cancer cell line NCI-H1975 was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

[0090] 2.3 Culture medium

[0091] RPMI 1640 basal medium and fetal bovine serum (FBS) were purchased from GIBCO (Grand Island, NY, USA), and Matrigel was purchased from Corning (Corning, NY, USA).

[0092] 3. Experimental Design

[0093] The experimental design is shown in Table 2.

[0094] Table 2 Experimental design of in vivo efficacy

[0095] 4. Experimental Methods

[0096] 4.1 Model establishment

[0097] NCI-H1975 cells were cultured in RPMI 1640 medium containing 10% FBS and maintained in a humidified cell culture incubator at 37°C with 5% CO2.

[0098] NCI-H1975 cells in the logarithmic growth phase were collected and resuspended in RPMI 1640 basal medium containing 50% Matrigel. The cell concentration was adjusted to 2×10 7 Under sterile conditions, 0.1 mL of cell suspension was inoculated subcutaneously on the right side of the mouse at a concentration of 2 × 10 6 / 0.1mL / mouse.

[0099] 4.2 Grouping and Dosing

[0100] When the average tumor volume reaches 150 mm 3 Around 24 h, the animals were randomly divided into groups according to tumor volume so that the difference in tumor volume between groups was less than 10% of the mean.

[0101] The day of grouping is designated as Day 0, and dosing will begin based on animal body weight. During dosing, if individual animals' body weight decreases by more than 15% compared to Day 0 (BWL ≥ 15%), drug treatment will be withheld and dosing will be resumed until the animal's body weight recovers (BWL < 15%).

[0102] 4.3 Weighing and observation

[0103] Animal body weight and tumor volume were measured twice a week during the experiment. Tumor length and width were measured with a digital caliper, and tumor volume was estimated based on these measurements.

[0104] During the experiment, the clinical symptoms of the animals were observed and recorded once a day. Clinical observations included the animals' overall health, abnormal weight, abnormal behavior, and other adverse reactions related to administration.

[0105] 4.4 Experimental endpoint description

[0106] According to animal welfare regulations, if any of the following conditions are met during the experiment, the animal will be removed from the experimental group and euthanized: 1. The animal's body weight decreases by more than 20% compared to Day 0 (BWL ≥ 20%); 2. The animal experiences severe adverse reactions such as blindness or paralysis; 3. The tumor volume is greater than 2000 mm 3; 4. Open ulcers form on the surface of the tumor.

[0107] After the final weighing on Day 21, the remaining animals were euthanized with CO2, and the tumors were removed, weighed, and photographed for record. The experiment was terminated.

[0108] 4.5 Evaluation indicators

[0109] Tumor volume (TV) is calculated as follows: 1 / 2×a×b 2 , where a and b are the length and width of the tumor, respectively.

[0110] Tumor growth inhibition rate (%TGI TV )The calculation formula is: (1-TV T / TV C )×100%, TV C is the average tumor volume of the negative control group, TV T is the average tumor volume of the treatment group.

[0111] The relative tumor volume (RTV) was calculated as: Vt / V0, where V0 was the tumor volume at the time of grouping and Vt was the tumor volume at each measurement.

[0112] Relative tumor proliferation rate (%T / C RTV ) is calculated as follows: RTV / C RTV × 100%, where T RTV RTV for the treatment group, C RTV RTV was the negative control group.

[0113] Tumor inhibition rate (% TGI TW )The calculation formula is: (TW C -TW T ) / TW C × 100%, of which TW C is the average tumor weight of the negative control group, TW T is the average tumor weight of the treatment group.

[0114] The formula for calculating the animal body weight change rate (%BWC) is: (BW t -BW0) / BW0×100%, where BW t is the weight of the animals at each measurement, and BW0 is the weight of the animals when they were grouped.

[0115] According to China NMPA's "Technical Guidelines for Non-clinical Studies of Cytotoxic Anti-tumor Drugs" (November 2006), %T / C RTVIf the mortality rate is less than 40% and P<0.05, the drug is considered effective. If the number of drug-related animal deaths exceeds 20%, the drug dose is considered to be severely toxic.

[0116] 5. Statistical Analysis

[0117] In this study, experimental data were expressed as Mean ± SEM.

[0118] The two-tailed t-test was used for comparison between groups, with P < 0.05 considered a significant difference and P < 0.01 considered an extremely significant difference (Microsoft Excel 2007, Redmond, WA, USA).

[0119] 6. Experimental Results

[0120] The effects of different drug combinations on animal body weight and mortality are shown in Table 3.

[0121] Table 3 Effects of different drug combinations on animal body weight

[0122] As shown in Table 3, the combined administration of the vehicle control group, the single-component AZD9291 and CAI of Comparative Examples 1-3, and the combination of Examples 1-2 showed no inhibitory effect on animal weight gain, as shown in Figure 1 . The average animal weight increased by 8.51%-11.04% (1.63 g-2.17 g) compared to the start of the experiment on Day 0, as shown in Figure 2 . No drug-related animal deaths or other significant drug-related side effects were observed during the experiment.

[0123] The effects of different drug combinations on tumor volume, weight and tumor inhibition rate are shown in Table 4.

[0124] Table 4 Effects of different drug combinations on tumor volume, weight and tumor inhibition rate

[0125] Compared with the control group, * P<0.05, ** P<0.01; compared with comparative example 1, # P<0.05; compared with comparative example 2, & P<0.05; compared with comparative example 3, ※ P<0.05.

[0126] The drug combination index is evaluated according to the following formula:

[0127] CI = E(A+B) / (EA+EB - EA×EB), where E(A+B) represents the combined inhibitory effect, EA represents the inhibitory effect of drug A, and EB represents the inhibitory effect of drug B. The numerator represents the "measured combined effect," and the denominator represents the "expected combined effect." A CI of 0.85-1.15 indicates a simple additive effect of the two drugs, >1.15 indicates enhancement (or synergy), and <0.85 indicates antagonism.

[0128] Combined tumor growth inhibition index: CAI, 40 mg / kg + AZD9291, 1 mg / kg: 1.27;

[0129] CAI,20mg / kg+AZD9291,1mg / kg: 1.18;

[0130] Combined tumor inhibition index: CAI, 40 mg / kg + AZD9291, 1 mg / kg: 1.20;

[0131] CAI,20mg / kg+AZD9291,1mg / kg: 1.62.

[0132] According to the data of tumor volume, weight and tumor inhibition rate in Table 4 and the comparative curves of tumor volume, relative tumor volume and tumor weight in Figures 3-5, in Comparative Example 1, the single component AZD9291 1 mg / kg dose was administered alone, the average tumor weight was 1.401 ± 0.212 g, and the tumor inhibition rate was % TGI. TW The relative tumor growth rate (%T / C) was 14.73%, which was not significantly different from the average tumor weight of the vehicle control group (1.643±0.250g) (P>0.05). RTV It was 81.08% (P>0.05).

[0133] In comparative example 2, the single component CAI 40 mg / kg dose was administered alone and in comparative example 3, the 20 mg / kg dose was administered alone. The average tumor weights were 1.384±0.266 g and 1.527±0.257 g, respectively. The tumor inhibition rate was %TGI. TW The relative tumor proliferation rate (%T / C) was 15.76% and 7.06%, respectively, which had no significant difference compared with the vehicle control group (P>0.05, P>0.05). RTV The rates were 93.04% (P>0.05) and 93.23% (P>0.05) respectively.

[0134] In Example 1, the combination of CAI 40 mg / kg and AZD9291 1 mg / kg was administered together, and the average tumor weight was 1.087±0.167 g, and the tumor inhibition rate was %TGI. TWThe relative tumor growth rate (%T / C) was 33.84%, which was significantly different from the average tumor weight of control group 1-2 and the vehicle control group (P < 0.05). RTV The results were 62.34% (P<0.01), which was significantly different from the control example 1 where AZD9291 1 mg / kg was administered alone (P<0.05), and compared with the control example 2 where CAI 40 mg / kg was administered alone (P<0.05).

[0135] In Example 2, the combination of CAI 20 mg / kg and AZD9291 1 mg / kg was administered together, and the average tumor weight was 1.090 ± 0.139 g, and the tumor inhibition rate was % TGI. TW The relative tumor growth rate (%T / C) was 33.66%, which was significantly different from the average tumor weight of control examples 1, 3 and the vehicle control group (P < 0.05). RTV The difference was 66.05% (P<0.01), which was significantly different from that of the single administration of AZD9291 1 mg / kg in Comparative Example 1 (P<0.05), and significantly different from that of the single administration of CAI 20 mg / kg in Comparative Example 3 (P<0.05).

[0136] Combined with the tumor comparison diagram at different times in Figure 6 and the above data, the results show that the combined administration of the composition CAI 40 mg / kg and AZD9291 1 mg / kg in Example 1 and the combined administration of CAI 20 mg / kg and AZD9291 1 mg / kg in Example 2 can significantly inhibit the growth and proliferation of human lung cancer NCI-H1975 xenograft tumors in nude mice (P<0.01, P<0.01). Combined with the evaluation of the drug combination index, it can be seen that the combined administration of CAI and AZD9291 in Examples 1-2 has a significant combined synergistic effect.

[0137] Example 3: Study on the efficacy of carboxyamide triazole combined with alectinib in vitro cell experiments

[0138] 1. Research Methods

[0139] The CCK8 assay was used to evaluate the effects of drugs on cell proliferation in lung cancer cell lines (NCI-H2228 cells). Cell viability was measured after treatment with different drug concentrations, and the 50% inhibitory concentration was calculated.

[0140] 2. Drugs and main reagents

[0141] The drugs and reagents involved in the in vitro cell efficacy study are shown in Table 5-6.

[0142] Table 5

[0143] Table 6

[0144] 3. Experimental Methods

[0145] 3.1 Cell recovery

[0146] NCI-H2228 cells (purchased from American Type Culture Collection (ATCC, Manassas, VA, USA)) were taken out of liquid nitrogen, thawed in a 37°C constant temperature water bath, and cultured in 1640 medium after recovery.

[0147] 3.2 Cell subculture and cell plating

[0148] When the cell density in the culture medium reached 90%, the cells were digested with 0.25% trypsin and resuspended. After the cell growth state stabilized, the cells in the logarithmic growth phase were harvested and counted using a cell counter to ensure that the viability of each cell line was above 85%.

[0149] Adjust the cell concentration by diluting with culture medium, add 100 μL of cell suspension to a 96-well cell plate to make the cell density reach 3000 cells / well, and add 100 μL of PBS buffer around the 96-well plate.

[0150] The cells in the 96-well plate were cultured overnight at 37°C, 5% CO2 and 95% humidity.

[0151] 3.3 Cell loading

[0152] Remove the cell culture plate from the incubator, remove the cell culture medium, and add the prepared drug-containing culture medium. Incubate at 37°C, 5% CO2, and 95% humidity for 72 hours.

[0153] 3.4CCK8 detection

[0154] Add 10 μL of CCK-8 solution to each well of a 96-well plate, incubate the plate in a cell culture incubator for 1.5 h, and measure the absorbance at 450 nm using a microplate reader.

[0155] 3.5 Data processing methods

[0156] The data were analyzed using GraphPad Prism 5.0 software, and the dose-effect curves were fitted using nonlinear S-curve regression to calculate the IC50 values.

[0157] Cell viability (%) = (OD test drug - OD culture medium control) / (OD cell control - OD culture medium control) × 100%.

[0158] The compound combination index analysis is calculated using the median effect principle. The formula for the combination index of two compounds is: CI = (D)1 / (Dx)1+(D)2 / (Dx)2

[0159] Where:

[0160] (D)1 - the concentration of compound 1 required to produce effect X when it works in combination with other compounds;

[0161] (D)2—the concentration of compound 2 required to produce effect X when it works in combination with other compounds;

[0162] (Dx)1——the concentration of compound 1 required to produce effect X when used alone;

[0163] (Dx)2 - the concentration of compound 2 required to produce effect X when used alone.

[0164] The CI value can be used to quantitatively determine the nature and strength of the interaction between different compounds (Table 2). The interaction is measured by the average CI value (Weighted Average CI, CIwt), the formula is: CIwt = (CI50 + 2CI75 + 3CI90 + 4CI95) / 10

[0165] Where:

[0166] CI50 – CI value at EC50 (concentration at which the effect reaches 50%);

[0167] The same applies to CI75, CI90, and CI95, which are the CI values ​​at EC75, EC90, and EC95, respectively.

[0168] 3.6 Result judgment criteria

[0169] Evaluation of combined effects: The combined effects were determined based on the CI values. The determination method is shown in Table 7 below.

[0170] Table 7 Result judgment criteria

[0171] 4. Test results

[0172] 4.1 Cell Observation

[0173] There was no drug precipitation or crystallization; NCI-H2228 cells had good viability, normal cell morphology, and no bacterial or fungal contamination.

[0174] 4.2 Test results

[0175] The IC50 values ​​of CAI alone in the NCI-H2228 cell line were 22.427, 22.877, and 23.018 μM, respectively, with an average of 22.774 μM. The IC50 values ​​of alectinib alone in the NCI-H2228 cell line were 0.563, 0.471, and 0.546 μM, respectively, with an average of 0.527 μM. Combination therapy with CAI resulted in IC50 values ​​of 1.660, 1.092, and 2.150 μM, with an average of 1.634 μM; while alectinib's IC50 values ​​were 0.332, 0.218, and 0.430 μM, with an average of 0.327 μM. The synergistic effect indices were 0.366, 0.203, and 0.540, respectively, with an average of 0.370. These results indicate a strong synergistic effect (+++) between CAI and alectinib, as shown in Table 8.

[0176] Table 8 Effects of CAI combined with alectinib on the activity of NCI-H2228 cells

[0177] 4.3 Conclusion

[0178] Under the experimental conditions, the results showed that the combination of CAI and alectinib had a strong synergistic effect in inhibiting the growth and proliferation of NCI-H2228 cells.

[0179] 2. Animal Experimental Efficacy Study of Carboxyamidotriazole Combined with Alectinib

[0180] 1. Experimental Animals

[0181] 1.1 Animal Information

[0182] BALB / c nude female mice, 8-10 weeks old, 18-20 g, with a deviation of approximately ±20% of the mean body weight. Number of animals vaccinated: 80, number of animals enrolled: 60.

[0183] Animal source: Jiangsu Jicui Yaokang Biotechnology Co., Ltd., production license number: SCXK(Su)2018-0008, animal certificate number: 202329657.

[0184] 1.2 Animal husbandry

[0185] Housing conditions: SPF environment, IVC mouse cages, 5 mice per cage, temperature: 20-26°C, humidity: 40-70%, light intensity: 12-hour day / night cycle. Feed: irradiated rat and mouse chow purchased from Beijing Keao Xieli Feed Co., Ltd., with ad libitum access. Drinking water: filtered, autoclaved tap water. Bedding: corn cobs purchased from Keao Xieli, autoclaved, and changed weekly.

[0186] Adaptive feeding: Before the experiment, mice were given an adaptive feeding period of no less than 7 days.

[0187] Animal identification: Each mouse cage is hung with an experimental information card, which includes mouse information, cell inoculation information, animal experiment information, and experimenter information. Mice are marked with ear tags.

[0188] 1.3 Laboratory Animal Operation and Management Standards

[0189] During the experiment, all experimental animals were kept in the SPF-level animal laboratory of Shanghai Medicilon Biotechnology Co., Ltd., and the animal laboratory personnel of Shanghai Medicilon Biotechnology Co., Ltd. were responsible for daily care and experimental research.

[0190] All operations and management of experimental animals strictly complied with the Shanghai Medicilon Guidelines for the Use and Management of Laboratory Animals.

[0191] 2. Experimental Materials

[0192] 2.1 Solvent formulation and storage conditions of dosing solution

[0193] 2.1.1 CAI

[0194] Solvent: 100% PEG400

[0195] Storage conditions of the dosing solution: Store at room temperature away from light, with a shelf life of 3 days.

[0196] 2.1.2 Alectinib

[0197] Solvent: 0.5% MC

[0198] Storage conditions of the dosing solution: Store at 4°C away from light, with a shelf life of 7 days.

[0199] 2.2 Cell lines

[0200] Human lung cancer cell line NCI-H2228 was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

[0201] 2.3 Culture medium

[0202] RPMI 1640 basal medium and fetal bovine serum (FBS) were purchased from GIBCO (Grand Island, NY, USA), and Matrigel was purchased from Corning (Corning, NY, USA).

[0203] 3. Experimental Design

[0204] The experimental design is shown in Table 9.

[0205] Table 9 Experimental design of in vivo efficacy

[0206] 4. Experimental Methods

[0207] 4.1 Model establishment

[0208] NCI-H2228 cells were cultured in RPMI 1640 medium containing 10% FBS and maintained in a humidified cell culture incubator at 37°C with 5% CO2.

[0209] NCI-H2228 cells in the logarithmic growth phase were collected and resuspended in RPMI 1640 basal medium containing 50% Matrigel. The cell concentration was adjusted to 2×10 7 Under sterile conditions, 0.1 mL of cell suspension was inoculated subcutaneously on the right side of the mouse at a concentration of 2 × 10 6 / 0.1mL / mouse.

[0210] 4.2 Grouping and Dosing

[0211] When the average tumor volume reaches 150 mm 3 Around 24 h, the animals were randomly divided into groups according to tumor volume so that the difference in tumor volume between groups was less than 10% of the mean.

[0212] The day of grouping is designated as Day 0, and dosing will begin based on animal body weight. During dosing, if individual animals' body weight decreases by more than 15% compared to Day 0 (BWL ≥ 15%), drug treatment will be withheld and dosing will be resumed until the animal's body weight recovers (BWL < 15%).

[0213] 4.3 Weighing and observation

[0214] The pharmacodynamic evaluation experiments were the same as those in Examples 1-2 and Comparative Examples 1-3.

[0215] 4.4 Experimental endpoint description

[0216] The pharmacodynamic evaluation experiments were the same as those in Examples 1-2 and Comparative Examples 1-3.

[0217] 4.5 Evaluation indicators

[0218] The pharmacodynamic evaluation experiments were the same as those in Examples 1-2 and Comparative Examples 1-3.

[0219] 5. Statistical Analysis

[0220] The pharmacodynamic evaluation experiments were the same as those in Examples 1-2 and Comparative Examples 1-3.

[0221] 6. Experimental Results

[0222] The effects of different drug combinations on animal body weight and mortality are shown in Table 10.

[0223] Table 10 Effects of different drug combinations on animal body weight

[0224] As shown in Table 10, the vehicle control group, the single-component CAI of Comparative Examples 4-6, and the combination of Examples 4-5 showed no inhibitory effect on animal weight gain, with average animal weight increasing by 1.56%-6.51% (0.56g-1.82g) compared to the start of the experiment on Day 0. Alectinib had a slight inhibitory effect on animal weight, with average animal weight decreasing by 1.13% (-0.28g) compared to the start of the experiment on Day 0. During the experiment, no drug-related animal deaths or other significant drug-related toxicities were observed.

[0225] The effects of different drug combinations on tumor volume, weight and tumor inhibition rate are shown in Table 11.

[0226] Table 11 Effects of different drug combinations on tumor volume, weight and tumor inhibition rate

[0227] Compared with the control group, * P<0.05, ** P<0.01; compared with comparative example 4, # P<0.05, ## P<0.01; compared with comparative example 5, & P<0.05, && P<0.01; compared with comparative example 6, ※ P<0.05, ※※ P<0.01.

[0228] According to the tumor volume, weight and tumor inhibition rate data in Table 11 and the comparative curves of tumor volume, relative tumor volume and tumor weight shown in Figures 7 to 9, in Comparative Example 4, when a single component Alectinib 1 mg / kg was administered alone, the average tumor weight was 0.444 ± 0.049 g, and the tumor inhibition rate % TGI was 0. TW The relative tumor growth rate (%T / C) was 49.14%, which was significantly different from the average tumor weight of the vehicle control group (0.873±0.103g) (P<0.01). RTV It was 59.77% (P<0.01).

[0229] In Comparative Example 5, when a single component CAI dose of 20 mg / kg was administered alone, and in Comparative Example 6, when a single component CAI dose of 40 mg / kg was administered alone, the average tumor weights were 0529±0.055 g and 0.498±0.059 g, respectively. The tumor inhibition rates (%TGITW) were 39.40% and 42.96%, respectively, which were not significantly different from those in the vehicle control group (P<0.01). The relative tumor proliferation rates (%T / CRTV) were 69.94% (P<0.05) and 68.46% (P<0.05), respectively.

[0230] In Example 4, the combination of CAI at a dose of 20 mg / kg and Alectinib at a dose of 1 mg / kg was administered together, and the average tumor weight was 0.291±0.028 g, and the tumor inhibition rate %TGITW was 66.67%, which were significantly different from the average tumor weights of Comparative Examples 4-5 and the vehicle control group (P<0.05, P<0.01). The relative tumor growth rate %T / CRTV was 44.57% (P<0.01), which was not significantly different from the administration of Alectinib 1 mg / kg alone in Comparative Example 4 (P>0.05), but was significantly different from the administration of CAI 20 mg / kg alone in Comparative Example 5 (P<0.01).

[0231] In Example 5, the combination of CAI at a dose of 40 mg / kg and Alectinib at a dose of 1 mg / kg was administered in combination, and the average tumor weight was 0.269±0.041 g, and the tumor inhibition rate %TGITW was 69.19%, which were significantly different from the average tumor weights of Comparative Examples 4, 6 and the vehicle control group (P<0.01); the relative tumor growth rate %T / CRTV was 40.00% (P<0.01), which was significantly different from the administration of Alectinib 1 mg / kg alone in Comparative Example 4 (P<0.05) and the administration of CAI 40 mg / kg alone in Comparative Example 6 (P<0.01).

[0232] The research results show that the combined administration of the composition CAI 20 mg / kg and Alectinib 1 mg / kg in Example 4 and the combined administration of CAI 40 mg / kg and Alectinib 1 mg / kg in Example 5 can significantly inhibit the growth and proliferation of human lung cancer NCI-H2228 xenograft tumors in nude mice (P<0.01, P<0.01). Combined with the evaluation of the drug combination index, it can be seen that the combined administration of CAI and Alectinib in Examples 4-5 has a significant combined synergistic effect.

[0233] The above detailed description is a specific description of one feasible embodiment of the present invention. This embodiment is not intended to limit the patent scope of the present invention. Any equivalent implementation or modification that does not depart from the present invention should be included in the scope of the technical solution of the present invention.

Claims

1. A combined drug for treating lung cancer, characterized in that: The combined drug comprises carboxyamide triazole and an anti-tumor targeted drug targeting gene mutation.

2. The combined drug according to claim 1, characterized in that: The anti-tumor targeted drug is selected from one or more of a targeted drug for EGFR gene mutation, a targeted drug for ALK gene rearrangement, a targeted drug for MET gene mutation, a targeted drug for ROS1 gene rearrangement, a targeted drug for BRAFV600 gene mutation and a targeted drug for RET fusion.

3. The combined drug according to claim 2, characterized in that: The targeted drug for positive EGFR gene mutation is selected from at least one of osimertinib, icotinib, gefitinib, afatinib, ametinib and dacomitinib; the targeted drug for positive ALK rearrangement is selected from at least one of crizotinib, alectinib, ceritinib, ensartinib and brigatinib.

4. The combined drug according to claim 2, characterized in that: The targeted drug for MET gene mutation is sirotinib; the targeted drug for ROS1 gene rearrangement positive is selected from at least one of crizotinib and entrectinib; the targeted drug for BRAFV600 gene mutation is selected from at least one of dabrafenib and trametinib; the targeted drug for RET fusion is pralatrexate.

5. The combined drug according to claim 3, characterized in that: The combined drug includes carboxyamidotriazole and osimertinib.

6. The combined drug according to claim 3, characterized in that: The combined drug includes carboxyamidotriazole and alectinib.

7. The combined drug according to claim 1, characterized in that: The dosage of the carboxyamide triazole for adults is 1-10 mg / kg; the dosage of the anti-tumor targeted drug for adults is 0.05-10 mg / kg.

8. Use of the combined drug according to any one of claims 1 to 7 in the preparation of anti-lung cancer drugs.

9. The use according to claim 8, characterized in that: The effects of the combined drug include one or more of reducing tumor volume, increasing tumor growth inhibition rate, reducing relative tumor volume, reducing relative tumor proliferation rate and increasing tumor inhibition rate.

10. A pharmaceutical composition, characterized in that The composition comprises the combined drug according to any one of claims 1 to 7, the composition is used for the preparation of an anti-lung cancer drug, and the dosage form of the composition is selected from oral liquid, capsule, oral suspension, solid dispersion, capsule, sustained release agent, granule, tablet, injection, ointment, patch or implant.

Citation Information

Patent Citations

  • Method for treating malignant tumors with joint medicament administration and anti-malignant tumor medicament

    CN101669941A

  • Anticancer sustained-released formulation loaded with blood vessel inhibitor and synergist thereof

    CN101336889A

  • Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

    CN105120663A

  • Application of CAI (Carboxyamidotriazole) and IDO1 (Indoleamine 2,3-Dioxygenase) inhibitor combination in resisting tumor

    CN109674788A

  • Application of CAI (Carboxyamidotriazole) and glutamate uptake and metabolic inhibitors in resisting tumor

    CN109674789A